Skip to main content
Roy Baynes, MD, Oncology, New York, NY

RoyDBaynesMDPhD

Oncology New York, NY

Hematologic Oncology

Executive Vice President and Chief Medical Officer, Eikon Therapeutics

Dr. Baynes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Baynes' full profile

Already have an account?

  • Office

    450 East 29th Street
    New York, NY 10016

Education & Training

  • University of the Witwatersrand
    University of the WitwatersrandClass of 1978

Certifications & Licensure

  • KS State Medical License
    KS State Medical License 1989 - 2019
  • MO State Medical License
    MO State Medical License 1995 - 2019

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Merck’s KEYTRUDA® (Pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients with Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 Expression
    Merck’s KEYTRUDA® (Pembrolizumab) Significantly Improved Disease-Free Survival (DFS) Versus Placebo as Adjuvant Therapy in Patients with Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) Regardless of PD-L1 ExpressionMarch 17th, 2022
  • Merck’s Keytruda Reduced Risk of Disease Recurrence or Death in Early Lung Cancer Patients by 24%
    Merck’s Keytruda Reduced Risk of Disease Recurrence or Death in Early Lung Cancer Patients by 24%March 17th, 2022
  • Pivotal Phase 3 Data for KEYTRUDA® (Pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of Medicine
    Pivotal Phase 3 Data for KEYTRUDA® (Pembrolizumab) in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC) Published in the New England Journal of MedicineFebruary 10th, 2022
  • Join now to see all